- Investors & Media
- Investors & Media
- Contact Us
The company will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.
The conpany announced today a collaboration with Massachusetts General Hospital (MGH) to conduct a proof of concept study evaluating the potential benefit of the Company's Liquid Alpha-1 Antitrypsin (AAT) on liver preservation.
Kamada announced today the appointment of Gwen A. Melincoff to the Company's Board of Directors.
Total revenues for 2016 were $77.5 million, an 11% increase over 2015. Full year 2016 Proprietary Product revenues up over 30%. Re-affirms revenue guidance of $100 million for 2017. Conference Call Today (Feb. 6) at 8:30am Eastern Time.
Kamada management will host an investment community conference call on Monday,
February 6 at 8:30 a.m. Eastern time to discuss these results and answer questions.
Kamada announced today the positive Scientific Advice response from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) focused on the Company's development program in Europe for Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (aGvHD) with lower gastrointestinal involvement.
Amir London, our CEO, explains in a special interview how Kamada saves lives and treats rare diseases with unique protein therapeutics.
The conpany announced today that it has signed a collaboration agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, for the development of an efficient and robust eukaryotic expression system for recombinant human Alpha 1 Antitrypsin (rhAAT). The goal of this development work is to maximize protein yields and functionality.
The company announced financial results for the third quarter and nine months of 2016. Conference call will be held at Nov.10th, 8:30am Eastern Time
Kedrion Biopharma, and Kamada Ltd. (NASDAQ and TASE: KMDA) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BL) for a human anti-rabies immunoglobulin (IgG) therapy